Perkins Capital Management’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Perkins Capital Management’s Portfolio IDXG Stock Details IDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$1.16M	Sell	224,107 -5,482	-2%	-$39.7K	1.4%	23
2019 Q4	$1.15M	Sell	229,589 -6,450	-3%	-$41.7K	1.03%	32
2019 Q3	$1.88M	Buy	236,039 +43,314	+22%	+$338K	1.62%	17
2019 Q2	$1.4M	Buy	192,725 +500	+0.3%	+$3.66K	0.98%	31
2019 Q1	$1.54M	Buy	192,225 +89,125	+86%	+$838K	1.01%	31
2018 Q4	$825K	Buy	103,100 +39,300	+62%	+$471K	0.64%	49
2018 Q3	$983K	Buy	+63,800	New	+$769K	0.59%	55

Other funds holding IDXG

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Perkins Capital Management's IDXG Position: Q1 2020 in Review

Perkins Capital Management reduced its Interpace Biosciences, Inc. Common Stock (IDXG) stake by 2.4% in Q1 2020, selling an estimated $39.7K and leaving 224,107 shares worth $1.16M. The position accounts for 1.4% of the portfolio, ranked #23.

Perkins Capital Management first reported a position in IDXG in Q3 2018 and has held it in 7 quarters since. The position peaked at $1.88M in Q3 2019. 15 funds tracked by Wall St. Rank hold IDXG as of Q1 2020.

Perkins Capital Management held 224,107 shares of Interpace Biosciences, Inc. Common Stock worth $1.16M as of Q1 2020.
Perkins Capital Management sold 5,482 Interpace Biosciences, Inc. Common Stock shares in Q1 2020, an estimated $39.7K.
Interpace Biosciences, Inc. Common Stock made up 1.4% of Perkins Capital Management's portfolio in Q1 2020, its #23 holding.
Perkins Capital Management first reported a position in Interpace Biosciences, Inc. Common Stock in Q3 2018 and has held it in 7 quarters since.
Perkins Capital Management's Interpace Biosciences, Inc. Common Stock position peaked at $1.88M in Q3 2019.
15 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2020.

Based on Perkins Capital Management's 13F filing for Q1 2020, filed 29 Apr 2020.